Golexin (Goserelin)

Golexin is indicated for several hormone‑sensitive conditions where reduction of sex hormone levels is therapeutic.

• Prostate cancer: used as adjunct therapy to lower testosterone levels and slow tumor progression.
• Breast cancer: administered to suppress estrogen production in hormone‑receptor‑positive disease.
• Endometriosis: helps relieve pelvic pain by reducing estrogen‑driven endometrial tissue growth.
• Uterine fibroids: decreases fibroid size and related symptoms through estrogen suppression.
• Precocious puberty: delays early sexual development by inhibiting gonadotropin release.

Side effects of Golexin reflect its hormonal suppression and may vary in frequency and severity.

Common

• Hot flashes or sudden feeling of warmth, often accompanied by sweating.
• Injection‑site pain, redness, or mild swelling at the subcutaneous administration site.
• Headache ranging from mild to moderate intensity.
• Fatigue or general lack of energy during the first weeks of therapy.
• Decreased libido and changes in sexual function.
• Mood swings, irritability, or mild depressive symptoms.

Serious

• Significant loss of bone mineral density, increasing fracture risk.
• Cardiovascular events such as hypertension, thromboembolic disease, or myocardial infarction.
• Severe allergic reactions, including anaphylaxis, rash, or angioedema.
• Pituitary apoplexy or other rare endocrine emergencies.

When prescribing Golexin, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline bone health; long‑term therapy may require calcium and vitamin D supplementation.
• Monitor cardiovascular risk factors, including blood pressure and lipid profile, before and during treatment.
• Evaluate liver and kidney function, as impairment may affect drug metabolism and excretion.
• Use caution in patients with a history of thromboembolic disease or uncontrolled hypertension.
• Discuss potential effects on fertility and advise appropriate contraceptive measures for reproductive‑age individuals.
• Consider the impact on growth and development when treating pediatric patients with precocious puberty.

Golexin may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use of other GnRH agonists or antagonists, which can amplify hormonal suppression.
• Strong CYP450 enzyme inducers that may reduce goserelin plasma concentrations.
• Medications known to increase the risk of thromboembolic events, such as estrogen‑containing hormone therapy.

Use with caution

• Anticoagulants, because altered hormone levels can affect coagulation parameters.
• Bisphosphonates or other bone‑active agents, requiring monitoring of bone density.
• Antidepressants or psychotropic drugs, as mood changes may be potentiated.
• Vaccines, particularly live attenuated vaccines, due to possible immune response modulation.